Regal Wealth Group’s Zevra Therapeutics ZVRA Stock Holding History

Regal Wealth Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15	Closed	–	–	254
2021 Q1	$0	Buy	+15	New	+$131	﹤0.01%	267

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Regal Wealth Group's ZVRA Position: Q2 2021 in Review

Regal Wealth Group sold out of Zevra Therapeutics (ZVRA) in Q2 2021, closing a stake of 15 shares.

Regal Wealth Group first reported a position in ZVRA in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 70 funds tracked by Wall St. Rank hold ZVRA as of Q2 2021.

Regal Wealth Group reported no remaining Zevra Therapeutics position as of Q2 2021 after selling out during the quarter.
Regal Wealth Group sold 15 Zevra Therapeutics shares in Q2 2021.
Regal Wealth Group first reported a position in Zevra Therapeutics in Q1 2021 and held it in 1 quarter.
Regal Wealth Group's Zevra Therapeutics position peaked at $0 in Q1 2021.
70 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2021.

Based on Regal Wealth Group's 13F filing for Q2 2021, filed 2 Aug 2021.